Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.90
-0.4900-2.01%
Post-market: 23.900.00000.00%19:30 EDT
Volume:496.35K
Turnover:12.03M
Market Cap:1.58B
PE:-7.69
High:25.56
Open:24.73
Low:23.77
Close:24.39
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:52.30M
Volume Ratio:1.00
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.37
PE(LYR):-9.47

Loading ...

Company Profile

Company Name:
Bicara Therapeutics
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
103
Office Location:
116 Huntington Avenue,Suite 703,Boston,Massachusetts,United States
Zip Code:
02116
Fax:
- -
Introduction:
Bicara Therapeutics Inc. was incorporated under Delaware law on December 12, 2018. The company is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, simultaneously targets the EGFR and TGF-β pathways and is currently being evaluated in a pivotal trial for head and neck squamous cell carcinoma.

Directors

Name
Position
Claire Mazumdar
Chief Executive Officer and Director
Michael Powell
Chairperson of the Board
Ryan Cohlhepp
President, Chief Operating Officer and Director
Carolyn Ng
Director
Christopher Bowden
Director
Heath Lukatch
Director
Jake Simson
Director
Kate Haviland
Director
Kiran Mazumdar Shaw
Director
Nils Lonberg
Director
Scott Robertson
Director
Vijay Kuchroo, D.V.M
Director

Shareholders

Name
Position
Claire Mazumdar
Chief Executive Officer and Director
Ryan Cohlhepp
President, Chief Operating Officer and Director
Ivan Hyep
Chief Financial Officer
David Raben
Chief Medical Officer
Lara Meisner
Chief Legal Officer